Introduction
The stats are stark: 63% of UK adults are overweight or obese, overburdening the NHS and leaving millions without timely care. But hope lies in scalable innovations like GLP-1 platforms and nutraceutical wellness. Health45 is investing in these ventures to drive accessible change—and attractive returns for forward-thinking investors.
Understanding the Crisis
Obesity isn’t just a numbers game; it’s a systemic issue tied to diet, lifestyle, and limited access to treatments. Breakthrough GLP-1 meds show promise, but distribution lags. Public systems can’t keep up, creating a $100B+ market gap in Europe. Nutraceuticals complement this by supporting prevention, turning wellness into a daily habit.
Health45’s Dual Approach: Platforms and Products
Our GLP-1 weight-loss platform democratizes access via app-based prescriptions and monitoring, while the nutraceutical line provides affordable adjuncts like fiber-enriched shakes. Together, they foster retention: users lose weight and maintain it, boosting long-term efficacy.
The Investor Perspective: Precision and Foresight
Led by private equity veterans, Health45 ensures strategic management. Offerings like Secured Loan Notes provide fixed 45% returns over three years, with capital protected through diversified structures. ESG focus means investments that align with societal good—reducing healthcare burdens.
Eligible investors, dive into our offerings now. Invest in Health Transformation.
